Is Eli Lilly's Management Charting the Right Course?

In the following video, Motley Fool healthcare analyst David Williamson takes a look at Eli Lilly's (NYSE: LLY  )  CEO, John Lechleiter, examining both how his background as a scientist makes him an a rarity in big pharma and highlighting his rise to the top of Eli Lilly. David then tells investors why Lechleiter's background is both a strength for the company -- and a potential weakness.

Is Eli Lilly a buy or sell?
With two of its top three drugs poised to lose patent protection this year, is Eli Lilly a dividend stock headed nowhere fast? In a new premium report, The Motley Fool's senior pharmaceuticals analyst breaks down all of Lilly's moving parts, including an in-depth analysis of the company's must-know opportunities and reasons to buy and sell today. To find out more click here to claim your copy today.

Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On March 24, 2013, at 11:15 AM, DannyHaszard wrote:

    Generic Zyprexa (Olanzapine) still a cash cow.

    There is a case to be made that the drug companies like Eli Lilly,knew exactly what they were doing to off-label Zyprexa.Zyprexa made them $70 billion dollars they paid no more than $4 billion in fines and lawsuits.-Daniel Haszard Zyprexa victim advocate.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2327944, ~/Articles/ArticleHandler.aspx, 11/26/2015 12:50:32 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Dave Williamson

The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...

Today's Market

updated 14 hours ago Sponsored by:
DOW 17,813.39 1.20 0.00%
S&P 500 2,088.87 -0.27 0.00%
NASD 5,116.14 0.00 0.00%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

11/25/2015 4:00 PM
LLY $83.74 Down -0.14 +0.00%
Eli Lilly & Co. CAPS Rating: ****
JNJ $101.96 Down -0.08 +0.00%
Johnson & Johnson CAPS Rating: ****
PFE $32.87 Up +0.90 +0.00%
Pfizer CAPS Rating: ****